Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

Franck Lemiale, Wing Pui Kong, Levent M. Akyürek, Xu Ling, Yue Huang, Bimal K. Chakrabarti, Michael Eckhaus, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

Replication-defective adenovirus (ADV) vectors represent a promising potential platform for the development of a vaccine for AIDS. Although this vector is typically administered intramuscularly, it would be desirable to induce mucosal immunity by delivery through alternative routes. In this study, the immune response and biodistribution of ADV vectors delivered by different routes were evaluated. ADV vectors expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env were delivered intramuscularly or intranasally into mice. Intranasal immunization induced greater HIV-specific immunoglobulin A (IgA) responses in mucosal secretions and sera than in animals with intramuscular injection, which showed stronger systemic cellular and IgG responses. Administration of the vaccine through an intranasal route failed to overcome prior ADV immunity. Animals exposed to ADV prior to vaccination displayed substantially reduced cellular and humoral immune responses to HIV antigens in both groups, though the reduction was greater in animals immunized intranasally. This inhibition was partially overcome by priming with a DNA expression vector expressing HIV-1 Gag, Pol, and Env before boosting with the viral vector. Biodistribution of recombinant adenovirus (rADV) vectors administered intranasally revealed infection of the central nervous system, specifically in the olfactory bulb, possibly via retrograde transport by olfactory neurons in the nasal epithelium, which may limit the utility of this route of delivery of ADV vector-based vaccines.

Original languageEnglish (US)
Pages (from-to)10078-10087
Number of pages10
JournalJournal of Virology
Volume77
Issue number18
DOIs
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

immunoglobulin A
Human immunodeficiency virus
Adenoviridae
Immunoglobulin A
central nervous system
Vaccines
Central Nervous System
HIV
vaccines
Human immunodeficiency virus 1
HIV-1
HIV Antigens
mucosal immunity
Central Nervous System Infections
AIDS Vaccines
Mucosal Immunity
animals
olfactory bulb
Nasal Mucosa
Olfactory Bulb

ASJC Scopus subject areas

  • Immunology

Cite this

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. / Lemiale, Franck; Kong, Wing Pui; Akyürek, Levent M.; Ling, Xu; Huang, Yue; Chakrabarti, Bimal K.; Eckhaus, Michael; Nabel, Gary J.

In: Journal of Virology, Vol. 77, No. 18, 09.2003, p. 10078-10087.

Research output: Contribution to journalArticle

Lemiale, Franck ; Kong, Wing Pui ; Akyürek, Levent M. ; Ling, Xu ; Huang, Yue ; Chakrabarti, Bimal K. ; Eckhaus, Michael ; Nabel, Gary J. / Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. In: Journal of Virology. 2003 ; Vol. 77, No. 18. pp. 10078-10087.
@article{1952c9fb06504b378dc56290ffc9c279,
title = "Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system",
abstract = "Replication-defective adenovirus (ADV) vectors represent a promising potential platform for the development of a vaccine for AIDS. Although this vector is typically administered intramuscularly, it would be desirable to induce mucosal immunity by delivery through alternative routes. In this study, the immune response and biodistribution of ADV vectors delivered by different routes were evaluated. ADV vectors expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env were delivered intramuscularly or intranasally into mice. Intranasal immunization induced greater HIV-specific immunoglobulin A (IgA) responses in mucosal secretions and sera than in animals with intramuscular injection, which showed stronger systemic cellular and IgG responses. Administration of the vaccine through an intranasal route failed to overcome prior ADV immunity. Animals exposed to ADV prior to vaccination displayed substantially reduced cellular and humoral immune responses to HIV antigens in both groups, though the reduction was greater in animals immunized intranasally. This inhibition was partially overcome by priming with a DNA expression vector expressing HIV-1 Gag, Pol, and Env before boosting with the viral vector. Biodistribution of recombinant adenovirus (rADV) vectors administered intranasally revealed infection of the central nervous system, specifically in the olfactory bulb, possibly via retrograde transport by olfactory neurons in the nasal epithelium, which may limit the utility of this route of delivery of ADV vector-based vaccines.",
author = "Franck Lemiale and Kong, {Wing Pui} and Aky{\"u}rek, {Levent M.} and Xu Ling and Yue Huang and Chakrabarti, {Bimal K.} and Michael Eckhaus and Nabel, {Gary J.}",
year = "2003",
month = "9",
doi = "10.1128/JVI.77.18.10078-10087.2003",
language = "English (US)",
volume = "77",
pages = "10078--10087",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "18",

}

TY - JOUR

T1 - Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

AU - Lemiale, Franck

AU - Kong, Wing Pui

AU - Akyürek, Levent M.

AU - Ling, Xu

AU - Huang, Yue

AU - Chakrabarti, Bimal K.

AU - Eckhaus, Michael

AU - Nabel, Gary J.

PY - 2003/9

Y1 - 2003/9

N2 - Replication-defective adenovirus (ADV) vectors represent a promising potential platform for the development of a vaccine for AIDS. Although this vector is typically administered intramuscularly, it would be desirable to induce mucosal immunity by delivery through alternative routes. In this study, the immune response and biodistribution of ADV vectors delivered by different routes were evaluated. ADV vectors expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env were delivered intramuscularly or intranasally into mice. Intranasal immunization induced greater HIV-specific immunoglobulin A (IgA) responses in mucosal secretions and sera than in animals with intramuscular injection, which showed stronger systemic cellular and IgG responses. Administration of the vaccine through an intranasal route failed to overcome prior ADV immunity. Animals exposed to ADV prior to vaccination displayed substantially reduced cellular and humoral immune responses to HIV antigens in both groups, though the reduction was greater in animals immunized intranasally. This inhibition was partially overcome by priming with a DNA expression vector expressing HIV-1 Gag, Pol, and Env before boosting with the viral vector. Biodistribution of recombinant adenovirus (rADV) vectors administered intranasally revealed infection of the central nervous system, specifically in the olfactory bulb, possibly via retrograde transport by olfactory neurons in the nasal epithelium, which may limit the utility of this route of delivery of ADV vector-based vaccines.

AB - Replication-defective adenovirus (ADV) vectors represent a promising potential platform for the development of a vaccine for AIDS. Although this vector is typically administered intramuscularly, it would be desirable to induce mucosal immunity by delivery through alternative routes. In this study, the immune response and biodistribution of ADV vectors delivered by different routes were evaluated. ADV vectors expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pol, and Env were delivered intramuscularly or intranasally into mice. Intranasal immunization induced greater HIV-specific immunoglobulin A (IgA) responses in mucosal secretions and sera than in animals with intramuscular injection, which showed stronger systemic cellular and IgG responses. Administration of the vaccine through an intranasal route failed to overcome prior ADV immunity. Animals exposed to ADV prior to vaccination displayed substantially reduced cellular and humoral immune responses to HIV antigens in both groups, though the reduction was greater in animals immunized intranasally. This inhibition was partially overcome by priming with a DNA expression vector expressing HIV-1 Gag, Pol, and Env before boosting with the viral vector. Biodistribution of recombinant adenovirus (rADV) vectors administered intranasally revealed infection of the central nervous system, specifically in the olfactory bulb, possibly via retrograde transport by olfactory neurons in the nasal epithelium, which may limit the utility of this route of delivery of ADV vector-based vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0141570410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141570410&partnerID=8YFLogxK

U2 - 10.1128/JVI.77.18.10078-10087.2003

DO - 10.1128/JVI.77.18.10078-10087.2003

M3 - Article

VL - 77

SP - 10078

EP - 10087

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 18

ER -